REHOVOT, Israel, Dec. 17, 2024 /PRNewswire/ -- Amai Proteins, a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of their proprietary hyper-sweet protein, sweelin®, on bloo...
SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder platform designed to selectively target tumor cells SK Biopharmaceuticals eyes innovative small protein-based radiopharmaceuticals on safety and effic...
Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON, South Korea, Dec. 17, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract ...
インプラントや関節置換術にExactech製品（Optetrak、Optetrak Logic、Truliant、Vantage、Connexion GXL、Equinoxe）が使用されている場合は、この通知にご注意ください。 ニューヨーク, 2024年12月17日 /PRNewswire/ -- 以下は Kroll Restructuring Administration LLCによって発表されています。 これは何についてですか? Exactech, Inc.は、関節置換用インプラントおよび関連する外科手術器具の設計、製造、販売を行っています。Exactech, Inc.およびその関...
CUPERTINO, Calif., Dec. 17, 2024 /PRNewswire/ -- Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the objective...
귀하가 받은 이식/치환 수술에 옵테트랙(Optetrak), 옵테트랙 로직(Optetrak Logic), 트룰리안트(Truliant), 밴티지(Vantage), 커넥션(Connexion) GXL, 에퀴녹스(Equinoxe) 등 이그잭텍(Exactech) 제품이 포함된 경우 이 보도 자료에 주의를 기울이는 것이 중요하다. 뉴욕, 2024년 12월 17일 /PRNewswire/ -- 아래 보도 자료는 크롤 리스트럭추어링 어드미니스트레이션(Kroll Restructuring Administration) LLC에서 배포한 것이다. 이 공...
If your implant/replacement involved Exactech products – including Optetrak, Optetrak Logic, Truliant, Vantage, Connexion GXL, and Equinoxe – your attention to this notice is important. NEW YORK, Dec. 17, 2024 /PRNewswire/ -- The following is being issued by Kroll Restructuring Administration LLC....
新加坡2024年12月16日 /美通社/ -- 鹏瑞利集团有限公司（"鹏瑞利集团"）很荣幸宣布，位于中国天津市的鹏瑞利综合医院（"天津鹏瑞利医院"）已成功通过该市卫健委的验收评审，并获得了《医疗机构执业许可证》，成为中国首家外商独资三级综合医院。该三级综合医院设置500张床位，总投资额约10亿元人民币，将很快开始运营。 2024年9月，中国三部门联合发布通知，允许在北京、天津等多个重点城市设立外商独资医院。已在医疗健康与养老领域深耕多年的鹏瑞利集团迅速响应，调整其医疗健康业务战略，积极采取行动以顺应政策导向。 天津鹏瑞利医院位于西青区，紧邻天津南站，是天津南站鹏瑞利国际健康商旅城医疗板块的...
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p
KOTA KINABALU, Malaysia, Dec. 16, 2024 /PRNewswire/ -- A groundbreaking new book by Professor Dr. Mike Chan, "STEM CELLS, PEPTIDES & IMMUNOTHERAPY: Handbook on Regenerative Medicine for Animals," introduces revolutionary stem cell therapies that promise to extend the health span and longevity of hor...
